on THERACLION (EPA:ALTHE)
Theraclion 2024 Review: Progress and Challenges
Theraclion, a company specializing in non-invasive ultrasound therapy, closes 2024 with significant progress. The pivotal clinical trial for SONOVEIN® met the FDA’s schedule, with treatment completion in June and a 12-month follow-up ongoing. Final results are expected in the summer of 2025, a crucial step to enter the US market.
The SONOVEIN® product continues to show its maturity, with more than 3,000 treatments carried out. In 2024, 29 presentations took place at 25 international events, strengthening the product's reputation.
Theraclion has also chosen to refocus on the varicose veins market. Turnover reached €1,485,000 excluding adjustments, marked by growth in sales of consumables (+9%). In 2025, the company plans to intensify its commercial development.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all THERACLION news